$1.13B in CY2024 Part D spend82K claims · 26K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Guselkumab used for?
TREMFYA is an interleukin-23 antagonist indicated for the treatment of: adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with moderate-to-severe plaque psoriasis....
Is there a generic for Guselkumab?
No. Guselkumab is brand-only with no generic equivalents currently in market.
How much does my plan pay for Guselkumab?
Across 329 Part D plans, Guselkumab averages $12295.24/unit (NADAC). Lowest available: $7349.67/unit. Highest in distribution: $14769.74/unit.
Is Guselkumab on the FDA shortage list?
No. Guselkumab is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (3 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.